Trial · NCT02249377
PRP vs Corticosteroid in Baker's Cyst
NCT02249377, Phase 3, Terminated, NYU Langone Health; results first posted 2020-03-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PRP vs Corticosteroid in Baker's Cyst. Trials, record NCT02249377. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02249377
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PRP vs Corticosteroid in Baker's Cyst
- NCT number
- NCT02249377
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 50 participants, actual
- Lead sponsor
- NYU Langone Health
- Conditions
- Baker's Cyst
- Interventions
- Platelets-Rich-Plasma, Corticosteroid
- First posted
- 2014-09-25
- Last updated
- 2020-03-18
- Results first posted
- 2020-03-18
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Outcome of Baker's Cysts With the Use of Platelets-Rich-Plasma Versus Corticosteroid | 6 Months | Outcome measure will be determined through the use of the Visual Analogue Score (VAS) and the Rauschning and Lindgren criteria which are used to clinically evaluate the presence of the popliteal cysts, pain, posterior sense of tension in the popliteal fossa and its clinical importance for range of motion reduction. The Knee Injury and Osteoarthritis Outcome Score (KOOS) will be used to assess short and long term outcome of knee related conditions. |
| Secondary | Recurrence of Baker's Cysts Treated on Each Group | 6 Months | Outcome measure will be determined through the use of the Visual Analogue Score (VAS) and the Rauschning and Lindgren criteria which are used to clinically evaluate the presence of the popliteal cysts, pain, posterior sense of tension in the popliteal fossa and its clinical importance for range of motion reduction. The Knee Injury and Osteoarthritis Outcome Score (KOOS) will be used to assess short and long term outcome of knee related conditions. |
| Secondary | Complications | 6 Months | All disease signs and symptoms experienced by the patient, as defined as an Adverse Event (AE), Treatment Emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Unexpected Adverse Device Effect (UADE), will be recorded from questionnaires during each study visit. |
| Secondary | Side Effects | 6 Months | All disease signs and symptoms experienced by the patient, as defined as an Adverse Event (AE), Treatment Emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Unexpected Adverse Device Effect (UADE), will be recorded from questionnaires during each study visit. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Outcome of Baker's Cysts With the Use of Platelets-Rich-Plasma Versus Corticosteroid | 6 Months | The study was terminated due to lack of funding. Efforts were made to collect data, but were unsuccessful. No study data are available. | ||
| SECONDARY | Recurrence of Baker's Cysts Treated on Each Group | 6 Months | The study was terminated due to lack of funding. Efforts were made to collect data, but were unsuccessful. No study data are available. | ||
| SECONDARY | Complications | 6 Months | The study was terminated due to lack of funding. Efforts were made to collect data, but were unsuccessful. No study data are available. | ||
| SECONDARY | Side Effects | 6 Months | The study was terminated due to lack of funding. Efforts were made to collect data, but were unsuccessful. No study data are available. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Platelets-Rich-Plasma Group | 25 | |
| Overall Study | STARTED | Corticosteroid Group: | 25 | |
| Overall Study | COMPLETED | Platelets-Rich-Plasma Group | 0 | |
| Overall Study | COMPLETED | Corticosteroid Group: | 1 | |
| Overall Study | NOT COMPLETED | Platelets-Rich-Plasma Group | 25 | |
| Overall Study | NOT COMPLETED | Corticosteroid Group: | 24 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Platelets-Rich-Plasma Group | 0 | 0 |
| Total, all-cause mortality | Corticosteroid Group: | 0 | 0 |
| Total, other adverse events | Platelets-Rich-Plasma Group | 0 | 0 |
| Total, other adverse events | Corticosteroid Group: | 0 | 0 |
| Total, serious adverse events | Platelets-Rich-Plasma Group | 0 | 0 |
| Total, serious adverse events | Corticosteroid Group: | 0 | 0 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02249377
GET https://conductscience.org/api/trials/v1/NCT02249377/registered